| Abstract |
【Abstract】Objective Analysis of escitalopram citalopram neurotransmitters in patients with coronary heart disease (CHD) with anxiety depression, brain derived neurotrophic factor (BDNF).Method Selection in May 2020 to May 2022 in our hospital for treatment of 80 patients with coronary heart disease (CHD) with anxiety depression as the research object, according to random number table method divided into observation group and control group, 40 cases in each.The control group was given conventional symptomatic treatment, and the observation group was given escitalopram with an initial dose of 5mg/d on the basis of the treatment of the control group, and the dose could be increased to 10-20mg /d after 3 days according to the actual situation of patients.Compare two groups before and after the treatment effect, Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD) scores, neurotransmitter levels , BDNF and serum lipoprotein (LP) and the incidence of adverse reactions.Result Observation group total effective rate is significantly higher than control group (P < 0.05);Two groups of HAMD, HAMA score decreased after treatment, observation group is lower than the control group (P < 0.05);In the two groups after treatment of neurotransmitter levels are rising, the observation group than the control group (P < 0.05);In the two groups after treatment of BDNF, higher level of LP, observation group is higher than the control group (P < 0.05);Incidence of adverse reactions to the two groups was no significant difference (P > 0.05).Conclusion Escitalopram can significantly improve the treatment effect of coronary heart disease patients with anxiety and depression, regulate negative emotions such as depression and anxiety, improve the levels of neurotransmitters, BDNF and LP, and has high safety, which is recommended for clinical application.
|